Literature DB >> 24408919

Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease.

Sylvia Plevritis1, Alexander R A Anderson2, Jill Gallaher2, Aravind Babu3.   

Abstract

To provide a better understanding of the relationship between primary tumor growth rates and metastatic burden, we present a method that bridges tumor growth dynamics at the population level, extracted from the SEER database, to those at the tissue level. Specifically, with this method, we are able to relate estimates of tumor growth rates and metastatic burden derived from a population-level model to estimates of the primary tumor vascular response and the circulating tumor cell (CTC) fraction derived from a tissue-level model. Variation in the population-level model parameters produces differences in cancer-specific survival and cure fraction. Variation in the tissue-level model parameters produces different primary tumor dynamics that subsequently lead to different growth dynamics of the CTCs. Our method to bridge the population and tissue scales was applied to lung and breast cancer separately, and the results were compared. The population model suggests that lung tumors grow faster and shed a significant number of lethal metastatic cells at small sizes, whereas breast tumors grow slower and do not significantly shed lethal metastatic cells until becoming larger. Although the tissue-level model does not explicitly model the metastatic population, we are able to disengage the direct dependency of the metastatic burden on primary tumor growth by introducing the CTC population as an intermediary and assuming dependency. We calibrate the tissue-level model to produce results consistent with the population model while also revealing a more dynamic relationship between the primary tumor and the CTCs. This leads to exponential tumor growth in lung and power law tumor growth in breast. We conclude that the vascular response of the primary tumor is a major player in the dynamics of both the primary tumor and the CTCs, and is significantly different in breast and lung cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24408919      PMCID: PMC3913019          DOI: 10.1158/0008-5472.CAN-13-0759

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.

Authors:  G Thomas Budd; Massimo Cristofanilli; Mathew J Ellis; Allison Stopeck; Ernest Borden; M Craig Miller; Jeri Matera; Madeline Repollet; Gerald V Doyle; Leon W M M Terstappen; Daniel F Hayes
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

3.  Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density.

Authors:  B V Offersen; M Borre; J Overgaard
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

Review 4.  Circulating tumor cells in prostate cancer: a potential surrogate marker of survival.

Authors:  Jérôme Doyen; Catherine Alix-Panabières; Paul Hofman; Scott K Parks; Emmanuel Chamorey; Hervé Naman; Jean-Michel Hannoun-Lévi
Journal:  Crit Rev Oncol Hematol       Date:  2011-06-15       Impact factor: 6.312

5.  Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes.

Authors:  Jung Eun Park; Hon Sen Tan; Arnab Datta; Ruenn Chai Lai; Huoming Zhang; Wei Meng; Sai Kiang Lim; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-02-01       Impact factor: 5.911

6.  Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination.

Authors:  Hari Prasad Dhakal; Bjørn Naume; Marit Synnestvedt; Elin Borgen; Rolf Kaaresen; Ellen Schlichting; Gro Wiedswang; Assia Bassarova; Karl-Erik Giercksky; Jahn M Nesland
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

7.  Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas.

Authors:  Anna S E Ljungkvist; Johan Bussink; Paulus F J W Rijken; Johannes H A M Kaanders; Albert J van der Kogel; Juliana Denekamp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

8.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

Review 9.  The growth rate of human tumours.

Authors:  G G Steel; L F Lamerton
Journal:  Br J Cancer       Date:  1966-03       Impact factor: 7.640

10.  Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study.

Authors:  P Eschwège; S Moutereau; S Droupy; R Douard; J-L Gala; G Benoit; M Conti; P Manivet; S Loric
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more
  10 in total

Review 1.  Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers.

Authors:  Robert Clarke; John J Tyson; Ming Tan; William T Baumann; Lu Jin; Jianhua Xuan; Yue Wang
Journal:  Endocr Relat Cancer       Date:  2019-06       Impact factor: 5.678

2.  Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach.

Authors:  Marc D Ryser; Walter T Lee; Neal E Ready; Kevin Z Leder; Jasmine Foo
Journal:  Cancer Res       Date:  2016-10-20       Impact factor: 12.701

3.  Modeling the effects of EMT-immune dynamics on carcinoma disease progression.

Authors:  Daniel R Bergman; Matthew K Karikomi; Min Yu; Qing Nie; Adam L MacLean
Journal:  Commun Biol       Date:  2021-08-18

4.  A filter-flow perspective of haematogenous metastasis offers a non-genetic paradigm for personalised cancer therapy.

Authors:  Jacob G Scott; Alexander G Fletcher; Philip K Maini; Alexander R A Anderson; Philip Gerlee
Journal:  Eur J Cancer       Date:  2014-10-08       Impact factor: 9.162

5.  Tissue-scale, personalized modeling and simulation of prostate cancer growth.

Authors:  Guillermo Lorenzo; Michael A Scott; Kevin Tew; Thomas J R Hughes; Yongjie Jessica Zhang; Lei Liu; Guillermo Vilanova; Hector Gomez
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-16       Impact factor: 11.205

6.  Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.

Authors:  Jian Yin; Yi Wang; Hanlu Yin; Wenping Chen; Guangfu Jin; Hongxia Ma; Juncheng Dai; Jiaping Chen; Yue Jiang; Hui Wang; Zhian Liu; Zhibin Hu; Hongbing Shen
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

7.  Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates.

Authors:  Xiaoqiang Sun; Jiguang Bao; Yongzhao Shao
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

8.  Cancer metastasis: enactment of the script for human reproductive drama.

Authors:  Xichun Sun; Xiwu Liu
Journal:  Cancer Cell Int       Date:  2017-05-02       Impact factor: 5.722

9.  Spatial Metrics of Tumour Vascular Organisation Predict Radiation Efficacy in a Computational Model.

Authors:  Jacob G Scott; Alexander G Fletcher; Alexander R A Anderson; Philip K Maini
Journal:  PLoS Comput Biol       Date:  2016-01-22       Impact factor: 4.475

Review 10.  The viable circulating tumor cells with cancer stem cells feature, where is the way out?

Authors:  Y T Luo; J Cheng; X Feng; S J He; Y W Wang; Q Huang
Journal:  J Exp Clin Cancer Res       Date:  2018-02-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.